



EFSI Operation Scoreboard¹

PROJECT PRESENTATION	
<u>Project name</u>	NEUROSCIENCE R&D AND INVESTMENT PROGRAMME
<u>Promoter or financial intermediary</u>	CORPORACION QUIMICO FARMACEUTICA ESTEVE SA
<u>Country of implementation</u>	Spain
<u>Summary project description</u>	The project concerns the Promoter's investments in Research and Development (R&D) in its Pharma and Chemical divisions and other related capex, notably: (i) the discovery and development of new products, (ii) the capex investments on its production centers in the Chemical division (two plants located in Spain), (iii) certain IT investments to upgrade the information systems, and (iv) investments aimed at improving the company's safety and environmental conditions.

¹ This Scoreboard of indicators reflects the information presented to the EFSI Investment Committee (IC) for its decision on the use of the EU guarantee for this operation. Therefore, the document does not take into account possible developments that could have occurred after this decision. Parts of this document that fall under the exceptions for disclosure defined by the EIB Group Transparency Policy, notably under the articles 5.5 (protection of commercial interests) and 5.6 (protection of the Bank's internal decision-making process), have been replaced by the symbol [...].

PROJECT PILLAR ASSESSMENT

Pillar 1

Contribution to EU policy	Significant
Cross-cutting objectives	
Climate Action	2.00%
EFSI	
Contribution to EFSI	100.00%
EFSI: Research, development and innovation	100.00%
Projects that are in line with Horizon 2020	100.00%

Pillar 2

Quality and soundness of the project	Excellent
1. Growth	[...]
2. Promoter capabilities	[...]
3. Sustainability	[...]
4. Employment	[...]

This pillar evaluates the quality and soundness of the operation. This pillar is composed of up to four indicators which include:

- (i) "Growth" i.e. for example and where relevant the economic rate of return ("ERR"), which considers the project's socioeconomic costs and benefits, including its spillover effects;*
- (ii) "Promoter capabilities" i.e. the capacity of the promoter/intermediary to implement the project and create the expected impact at the [final] beneficiary level;*
- (iii) "Sustainability" i.e. environmental and social sustainability²;*
- (iv) "Employment" i.e. the project's direct employment effect;*
- (v) "Increasing access to finance and improving financing conditions including for final beneficiaries".*

Pillar 3

EIB Technical and financial contribution to the project	Significant
1. Financial contribution	[...]
2. Financial facilitation	[...]
3. Advice	[...]

This pillar measures the EIB's particular contribution to the project and its financing scheme in the form of financial and non-financial benefits which go beyond what commercial players would normally be able to offer. This dimension of value added is assessed through up to three indicators:

- (i) "Financial Contribution" i.e. improving the counterpart's funding terms compared to market sources of finance (interest rate reduction and/or longer lending tenor),*
- (ii) "Financial Facilitation" i.e. helping to attract private financiers (for example through positive signaling effects), promoting synergies in co-financing with other public sources of funds including National Promotional Banks or EU financial instruments,*
- (iii) "Technical Contribution and Advice" i.e. providing advice with a view to optimizing the financing package (financial structuring), or technical advisory services in the form of expert input / knowledge transfer – provided in-house by the EIB or in the form of assignments to external consultants – to facilitate the preparation or implementation of a project.*

² For additional information on the EIB's assessment of the project's environmental and social aspects, please refer to the project's Environmental and Social Data Sheet (ESDS) published on the EIB website.

Pillar 4 – Complementary indicators

Additionality

In line with the EFSI objective of supporting research, development and innovation (RDI) under the scope of the Horizon 2020 programme, the operation will allow the promoter to execute high quality R&D activities in products and services that are expected to improve the lives of patients suffering from neurological conditions. The project will enable the promoter to retain its leading knowledge and long-term competitiveness in the sector, thus contributing to Europe's industrial and R&D competitiveness and economic growth, as well as to help to maintain highly skilled staff engaged in R&D activities in Europe.

The financing of this project supports RDI activities, which generate significant positive knowledge and technology externalities, through the creation of innovative processes, products and services and through skills development and upgrading.

The promoter is a privately owned pharmaceutical company. Long term financing for RDI projects is generally not available from commercial banks to cover the full investment needs due to the significant size of the investments and the inherent risk of a pharmaceutical industry for newly developed products. The promoter is thus facing a sub-optimal investment situation whereby it needs to make strategic choices regarding the priorities within its pipeline and the development programmes to pursue.

The project is expected to be classified under the EIB Special Activities category, in particular due to the long tenor of the loan and the uncertainty of outcomes of R&D investments for specialty care areas.

The financing provided by the EIB with the support of EFSI is expected to result in a quality stamp on the operation. The EIB operation is expected to crowd-in private sector financing and to increase the commercial banks confidence in the Promoter's long-term sustainability and its future investment plans.

The operation will be the first for the EIB with the Promoter.

Set of indicators related to the macroeconomic environment

Spain - Economic environment

Economic Performance

	ES	EU	US	ES
	2017	2017	2017	2001-2007
GDP per capita (EUR, PPS)	27,719	29,008	43,470	28,708
GDP growth (%)	3.0	2.4	2.2	3.6
Potential GDP growth (%)	1.0	1.8	2.0	3.6
Output gap (% of potential GDP)	-0.35	0.08	0.04	2.7
Unemployment Rate (%)	16.5	7.3	4.1	10.0
Unemployment Rate (%) - Y/Y change (% points)	-2.0	-0.9	-0.6	-0.34
Bank-interest rates to non-financial corporations (%)	1.6	1.3	2.4	3.8
Bank-interest rates to non-financial corporations (%) - Y/Y change (% points)	0	-0.04	0.4	-0.05
Investment rate (GFCF as % of GDP) - Total	20.5	20.2	20.5	28.7
Investment rate (GFCF as % of GDP) - Public	2.0	2.7	3.3	4.1
Investment rate (GFCF as % of GDP) - Private	18.5	17.4	17.2	24.6

General Sector Indicators

	2013	2014	2015	2016	EU (latest available)
Value added in Manufacture of basic pharmaceutical products and pharmaceutical preparations (% of total)	--	--	--	--	0.7
Employment in Manufacture of basic pharmaceutical products and pharmaceutical preparations (% of total)	--	--	--	--	0.3

Health

	2013	2014	2015	2016	EU (latest available)
Life expectancy (years)	83.2	83.3	83.0	--	80.6
Healthy life years at birth (Males)	64.7	65.0	--	--	61.4
Healthy life years at birth (Females)	63.9	65.0	--	--	61.8
Old age dependency ratio (65+/ 15-64 years)	26.3	27.2	27.9	28.3	29.3
Perinatal mortality per 1,000 live births	4.6	--	--	--	--
Hospital beds per 100,000 inhabitants	296.3	296.8	--	--	521.2

- Country average for "GDP per capita (EUR, PPS)" is calculated in real terms
- EU value for "Bank-interest rates to non-financial corporations" corresponds to Euro Area average; Country average is the simple average between 2003 and 2007
- The EU value is displayed as the value in the year that corresponds to the latest value of the indicator in a particular country

Other indicators³

Key project characteristics

	Expected at PCR
Start of works	01.01.2019
End of works	31.12.2022
Project investment cost	222.00 MEUR
EIB/EFSI eligible investment mobilised	222.00 MEUR
External EFSI multiplier	2.02
External EIB (non-EFSI) multiplier	
Amount of private financing	112.00 MEUR
Quick start (% of expenditure during 2015-2018)	
Co-financing with national promotional banks	0.00 MEUR
Co-financing with structural funds (ESIF)	0.00 MEUR
Co-financing with other EU instruments (i.e. Horizon 2020, Connecting Europe Facility, etc)	
Energy efficiencies realised	0.00 MWh/a
Climate Action indicator	2.00% Mitigation - RDI (transversal)
Employment during construction - temporary jobs	904 person years
Employment during operation - new permanent jobs	10 FTE

³ For additional information on the EIB's assessment of the project's environmental and social aspects, please refer to the project's Environmental and Social Data Sheet (ESDS) published on the EIB website. The abbreviation PCR stands for Project Completion Report. If applicable, a difference between the amount of Project investment costs and EIB/EFSI eligible investment mobilized might derive from the fluctuation of the underlying exchange rate.